Race Oncology Management
Management criteria checks 1/4
Race Oncology's CEO is Daniel Tillett, appointed in Nov 2023, has a tenure of less than a year. total yearly compensation is A$1.12M, comprised of 13% salary and 87% bonuses, including company stock and options. directly owns 10.13% of the company’s shares, worth €18.96M. The average tenure of the management team and the board of directors is 0.8 years and 1.8 years respectively.
Key information
Daniel Tillett
Chief executive officer
AU$1.1m
Total compensation
| CEO salary percentage | 13.0% |
| CEO tenure | less than a year |
| CEO ownership | 10.1% |
| Management average tenure | less than a year |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$1m | AU$145k | -AU$14m |
| Mar 31 2024 | n/a | n/a | -AU$12m |
| Dec 31 2023 | n/a | n/a | -AU$11m |
| Sep 30 2023 | n/a | n/a | -AU$11m |
| Jun 30 2023 | AU$836k | AU$332k | -AU$10m |
| Mar 31 2023 | n/a | n/a | -AU$10m |
| Dec 31 2022 | n/a | n/a | -AU$11m |
| Sep 30 2022 | n/a | n/a | -AU$11m |
| Jun 30 2022 | AU$1m | AU$228k | -AU$11m |
| Mar 31 2022 | n/a | n/a | -AU$10m |
| Dec 31 2021 | n/a | n/a | -AU$9m |
| Sep 30 2021 | n/a | n/a | -AU$8m |
| Jun 30 2021 | AU$1m | AU$167k | -AU$6m |
| Mar 31 2021 | n/a | n/a | -AU$5m |
| Dec 31 2020 | n/a | n/a | -AU$4m |
| Sep 30 2020 | n/a | n/a | -AU$4m |
| Jun 30 2020 | AU$147k | n/a | -AU$4m |
Compensation vs Market: Daniel's total compensation ($USD772.15K) is about average for companies of similar size in the German market ($USD815.10K).
Compensation vs Earnings: Daniel's compensation has increased whilst the company is unprofitable.
CEO
Daniel Tillett
less than a year
Tenure
AU$1,118,157
Compensation
Dr. Daniel Tillett has been Chief Executive Officer of Race Oncology Limited since November 22, 2023 and serves as its Managing Director and Director since September 1, 2024. He served as Non-Executive Dir...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.3yrs | AU$327.72k | no data | |
| CEO, Managing Director & Director | less than a year | AU$1.12m | 10.13% A$ 19.0m | |
| Chief Medical Officer | 1.2yrs | AU$704.81k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Vice President of Operations & Strategy | less than a year | no data | no data | |
| Company Secretary | 8.3yrs | no data | no data |
0.8yrs
Average Tenure
Experienced Management: FN3's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.3yrs | AU$327.72k | no data | |
| CEO, Managing Director & Director | no data | AU$1.12m | 10.13% A$ 19.0m | |
| Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Clinical Advisory Board | 4.8yrs | AU$815.36k | no data | |
| Member of Clinical Advisory Board | 4.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
| Clinical Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Non-Executive Director | no data | no data | no data |
1.8yrs
Average Tenure
Experienced Board: FN3's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.